MEREO BIOPHARMA ($MREO) posted quarterly earnings results for Q3 2026 on Monday, November 9th. The company reported earnings of -$0.01 per share, beating estimates of -$0.01 by $0.00. The company also reported revenue of $800,000, beating estimates of $0 by $800,000.
You can see Quiver Quantitative's $MREO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MEREO BIOPHARMA Hedge Fund Activity
We have seen 22 institutional investors add shares of MEREO BIOPHARMA stock to their portfolio, and 32 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC removed 12,368,855 shares (-92.5%) from their portfolio in Q2 2026, for an estimated $3,929,585
- NEWTYN MANAGEMENT, LLC removed 4,079,056 shares (-57.6%) from their portfolio in Q2 2026, for an estimated $1,295,916
- MILLENNIUM MANAGEMENT LLC removed 3,559,103 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,130,727
- TWO SIGMA INVESTMENTS, LP added 1,131,402 shares (+602.3%) to their portfolio in Q2 2026, for an estimated $359,446
- ISHARA INVESTMENTS LP added 768,750 shares (+inf%) to their portfolio in Q2 2026, for an estimated $244,231
- JANE STREET GROUP, LLC added 634,971 shares (+453.6%) to their portfolio in Q2 2026, for an estimated $201,730
- MARSHALL WACE, LLP removed 507,103 shares (-73.8%) from their portfolio in Q2 2026, for an estimated $161,106
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
